The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 23, 2021
Filed:
Nov. 28, 2017
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventors:
Marcus Kelly, New York, NY (US);
Jessica Kirshner, New York, NY (US);
Gavin Thurston, Briarcliff Manor, NY (US);
Assignee:
REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 31/565 (2006.01); A61K 31/198 (2006.01); A61K 31/27 (2006.01); C07K 14/575 (2006.01); C07K 14/72 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6811 (2017.08); A61K 31/198 (2013.01); A61K 31/27 (2013.01); A61K 31/565 (2013.01); A61K 39/3955 (2013.01); A61K 47/6803 (2017.08); A61K 47/6855 (2017.08); C07K 14/57554 (2013.01); C07K 14/72 (2013.01); C07K 16/2869 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract
Provided herein are methods of treating prolactin receptor positive breast cancer using an antibody drug conjugate (ADC) comprising an anti-PRLR antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent. In certain embodiments, the anti-PRLR antibody or antigen-binding fragment thereof is conjugated to maytansinoid. In certain embodiments, the method of treating PRLR positive breast cancer includes administering the ADC in combination with one or more chemotherapeutic agents.